Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate

Neuropsychopharmacology

Volumn 36, Issue 6, 2011, Pages 1178-1186

  Umhau, John C ^a   Schwandt, Melanie L ^a   Usala, Julie ^a   Geyer, Christopher ^a   Singley, Erick ^a   George, David T ^a   Heilig, Markus ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

acamprosate; alcoholism; craving; meta chlorophenylpiperazine; yohimbine

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ACAMPROSATE; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; PROLACTIN; SODIUM CHLORIDE; YOHIMBINE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SEEKING BEHAVIOR; DRUG SENSITIVITY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATE TRAIT ANXIETY INVENTORY; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADULT; ALCOHOL DETERRENTS; ALCOHOL-INDUCED DISORDERS, NERVOUS SYSTEM; ALCOHOLISM; ANXIETY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLACEBOS; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TAURINE; TREATMENT FAILURE; YOHIMBINE;

EID: 79954623890     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.253     Document Type: Article

References (54)

1. Anton RF, Moak DH, Latham PK (1996). The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 53: 225-231. (Pubitemid 26085204)
2. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998). Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcohol ClinExp Res 22: 573-579. (Pubitemid 28242460)
3. Bohn MJ, Krahn DD, Staehler BA (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19: 600-606.
4. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT (1986). Understanding and preventing relapse. Am Psychol 41: 765-782.
5. Charney DS, Woods SW, Goodman WK, Heninger GR (1987). Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144: 1030-1036. (Pubitemid 17143562)
6. Chick J, Howlett H, Morgan MY, Ritson B (2000). United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176-187. (Pubitemid 30248621)
7. Cooney NL, Litt MD, Morse PA, Bauer LO, Gaupp L (1997). Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. J Abnorm Psychol 106: 243-250. (Pubitemid 27184745)
8. Epstein DH, Preston KL, Stewart J, Shaham Y (2006). Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 189: 1-16. (Pubitemid 44607255)
9. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version. American Psychiatric Press: Washington DC.
10. Flannery BA, Poole SA, Gallop RJ, Volpicelli JR (2003). Alcohol craving predicts drinking during treatment: an analysis of three assessment instruments. J Stud Alcohol 64: 120-126. (Pubitemid 36194067)
11. Flannery BA, Volpicelli JR, Pettinati HM (1999). Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23: 1289-1295. (Pubitemid 29409341)
12. Fox HC, Bergquist KL, Hong KI, Sinha R (2007). Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals. Alcohol: Clin Exp Res 31: 395-403. (Pubitemid 46239271)
13. Funk CK, O'Dell LE, Crawford EF, Koob GF (2006). Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 26: 11324-11332. (Pubitemid 44772162)
14. Gehlert DR, Cippitelli A, Le AD, Hipskind PA, Hamdouchi C et al. (2007). 3-(4-chloro-2morpholin-4-yl-thiazol-5-yl)-8-(1-ethypro-pyl)-2, 6-dimethly-imidazo[1,2-b]pyridazine:a novel brain-pene-trant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27: 2718-2726. (Pubitemid 46393604)
15. George DT, Benkelfat C, Rawlings RR, Eckardt MJ, Phillips MJ, Nutt DJ et al (1997). Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. Am J Psychiatry 154: 81-87. (Pubitemid 27020197)
16. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C et al (2008). Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539. (Pubitemid 351398184)
17. Goldberg MR, Robertson D (1983). Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev 35: 143-180. (Pubitemid 14216352)
18. Hammarberg A, Beck O, Eksborg S, Jayaram-Lindstrom N, Lindefeldt A, Andersson M et al (2010). Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers. Ther Drug Monit 32: 489-496.
19. Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS (2009). The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 205: 53-62.
20. Heilig M, Egli M (2006). Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharm Therap 111: 855-876. (Pubitemid 44118437)
21. Heilig M, Koob GF (2007). A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30: 399-406. (Pubitemid 47090230)
22. Heinz A, Lober S, Georgi A, Wrase J, Hermann D, Rey ER et al (2003). Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 38: 35-39. (Pubitemid 36204362)
23. Hillemacher T, Bayerlein K, Wilhelm J, Frieling H, Sperling W, Kornhuber J et al (2006). Prolactin serum levels and alcohol craving - an analysis using Lesch's typology. Neuropsychobiology 53: 133-136. (Pubitemid 43854171)
24. Kranzler HR, Mulgrew CL, Modesto-Lowe V, Burleson JA (1999). Validity of the obsessive compulsive drinking scale (OCDS): does craving predict drinking behavior? Alcohol Clin Exp Res 23: 108-114. (Pubitemid 29068473)
25. Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS (1994). Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry 51: 898-911. (Pubitemid 24335957)
26. Le AD, Harding S, Juzytsch W, Funk D, Shaham Y (2005). Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psycho-pharmacology (Berl) 179: 366-373.
27. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000). The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psycho-pharmacology(Berl) 150: 317-324. (Pubitemid 30447852)
28. Litt MD, Cooney NL (1999). Inducing craving for alcohol in the laboratory. Alcohol Res Health 23: 174-178.
29. Litt MD, Cooney NL, Morse P (2000). Reactivity to alcohol-related stimuli in the laboratory and in the field: predictors of craving in treated alcoholics. Addiction 95: 889-900. (Pubitemid 30418979)
30. Littleton J, Zieglgansberger W (2003). Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12(Suppl 1): S3-S11. (Pubitemid 36583412)
31. Liu X, Weiss F (2002). Additive effort of stress and drug cues on reinstatement of ethanol seeking:exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and apioid mechanisms. J Neurosci 22: 7856-7861. (Pubitemid 35379090)
32. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y et al (2007). The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psycho-pharmacology (Berl) 195: 345-355. (Pubitemid 350160269)
33. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G et al (1992). The fifth edition of the addiction severity index. J Subst Abuse Treat 9: 199-213.
34. 0Brien CP, Kleber HD (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284: 1689-1695.
35. Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM et al (1993). Alcohol cue reactivity: effects of detoxification and extended exposure. J Stud Alcohol 54: 235-245. (Pubitemid 23101830)
36. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al (2006). Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101: 1451-1462. (Pubitemid 44337770)
37. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (Berl) 160: 19-29. (Pubitemid 34169822)
38. Ooteman W, Koeter MW, Verheul R, Schippers GM, Van den Brink W (2007). The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendo-crine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 17: 558-566. (Pubitemid 46778886)
39. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995). Double-blind randomized multicenter trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30: 239-247.
40. Pelc I, Verbanck P, Lebon O, Gavrilovic M, Lion K, Lehert P (1997). Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients - A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171: 73-77.
41. Sinha R (2009). Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict Biol 14: 84-98.
42. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ (2006). Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 63: 324-331. (Pubitemid 43345357)
43. Sinha R, O'Malley SS (1999). Craving for alcohol: findings from the clinic and the laboratory. Alcohol Alcohol 34: 223-230. (Pubitemid 29213716)
44. Skinner H, Horn J (1984). Alcohol Dependence Scale: User's Guide. Addiction Research Foundation: Toronto.
45. Sobell LC, Sobell MB (1992). Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten R (eds). Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Humana Press: Totowa, NJ. pp 41-72.
46. Southwick SM, Krystal JH, Bremner JD, Morgan III CA, Nicolaou AL, Nagy LM et al (1997). Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 54: 749-758. (Pubitemid 27344103)
47. Spanagel R, Sillaber I, Zieglgansberger W, Corrigall WA, Stewart J, Shaham Y (1998). Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology (Berl) 139: 391-401. (Pubitemid 28435036)
48. Spielberger CD, Gorsuch RL, Lushene RE (1970). Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press: Palo Alto.
49. Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH (2002). Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51: 642-651. (Pubitemid 34310501)
50. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84: 1353-1357. (Pubitemid 19281139)
51. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000). Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202-209. (Pubitemid 30248625)
52. Tiffany ST (1990). A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Rev 97: 147-168.
53. Tiffany ST, Wray J (2009). The continuing conundrum of craving. Addiction 104: 1618-1619.
54. Wilde MI, Wagstaff AJ (1997). Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53: 1038-1053. (Pubitemid 27254576)